- Our Services
- Platforms
- Target Solutions
- Technologies
- Service Types
- Our Science
- About Us
- Contact us
In this webinar, Dr. Rajendra Kumari and Dr. Gera Goverse discuss the basics of immuno-oncology and how cancer immunotherapies are studied along each step of the cancer immunity cycle.
An overview of in vivo, ex vivo and in vitro assays available, including both traditional as well as novel assays is presented. The speakers also describe the importance and applications of several technology platforms including flow cytometry, histology, single cell analysis, cytokine profiling, T cell cytotoxicity, and high content imaging, and highlight relevant examples from the literature that used them.
What is the cancer immunity cycle? How are the steps of the cycle regulated, and which steps are potential targets for immunotherapeutics?
Understand the advantages and limitations of 2D, 3D, in vivo, and ex vivo models
Applications of high-content imaging and why HCI analysis is so valuable for preclinical immuno-oncology research
Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience
As Executive Director of Integrated Solutions within the Commercial and Strategic Development team, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held post doctoral fellowships and Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham where she developed in vitro and in vivo preclinical models including patient-derived systems and imaging capabilities. Rajendra also co-founded PRECOS Ltd in 2010, serving as COO and then following merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.
Gera Goverse, PhD, Director, Immuno-oncology, Crown Bioscience
Dr. Gera Goverse joined OcellO in 2017 and is Director of Immuno-Oncology at Crown Bioscience Netherlands. Her expertise is in assay development for testing drug candidates targeting the immune cell response leading to the killing of tumors in 3D high content image assays.
Dr. Goverse who obtained her PhD in Immunology at the VU Medical Centre Amsterdam and continued her post-doctoral studies at the KU Leuven, applies her obtained knowledge within these complex assays studying different subsets of immune cells and is specialized in the role of the myeloid cell compartment.
